FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4384559860> ?p ?o ?g. }

• W4384559860 abstract "Background: It is claimed that breast cancer is the most common and devastating disease. Different anticancer drugs are used to treat different types of tumors with drug categories affecting abnormal cells in many ways. For adjuvant treatment, researchers have shown that certain chemotherapy drug combinations are sometimes more effective than single drug treatment. To treat a breast tumour, chemotherapy drugs or their combinations may be given as adjuvant therapies such as doxorubicin plus cyclophosphamide (AC) and docetaxel plus cyclophosphamide (TC) which is the focus of this research. Aim and Objectives: The aim of the study is to determine the better drug combination either Docetaxel or Doxorubicin in combination with Cyclophosphamide in patients with breast cancer. The objective of the study is compare the outcomes of the Chemotherapeutic drug combinations in terms of Disease-free Survival and Overall Survival rates. Methodology: It is a Retrospective Comparative study between the Two adjuvant chemotherapy drug combinations used in Breast Cancer Treatment i.e., Docetaxel with Cyclophosphamide vs Doxorubicin with Cyclophosphamide. The Patients data were collected based upon the Inclusion and Exclusion Criteria. Then they were randomly allocated into two groups by random sampling technique. One group (Group A) received Standard Adjuvant Chemotherapy Regimen Doxorubicin and Cyclophosphamide (AC), Whereas another group (Group B) received Docetaxel and Cyclophosphamide (AT) for 3 to 4 cycles depending on the Patient condition, data were collected and compared in terms of Primary end points on Disease Free Survival (DFS), Overall Survival (OS), and relapse rate to find out the better adjuvant chemotherapeutic regimen in the treatment of Breast Cancer. The Standard Dose of two drug combinations administered to the Groups A and B are Group A: 1. Doxorubicin 60mg and 2. Cyclophosphamide 600mg/m2 , whereas Group B received 1. Docetaxel 75mg and 2. Cyclophosphamide 600mg/m2 Conclusion: This retrospective study compared the Adjuvant TC regimen (Docetaxel with Cyclophosphamide) with the sequential regular Classical regimen of AC (Doxorubicin with Cyclophosphamide) in terms of the Progression Free Survival and Disease-free Survival. It is found that as far as Progression Free Survival is considered, there are no significant differences between the Both AC and TC regimen, But When Overall Survival is concerned, the TC Regimen is better drug Combination in treating the Breast Cancer. Both Treatment Regimens (TC & AC) was well tolerated with respect to Prognostic Factors, but as far as Adverse Effects and overall survival is considered, TC Regimen (Docetaxel and Cyclophosphamide) is better tolerated and can be recommended Adjuvant Cancer chemotherapeutic regimen in Breast Cancer Patients" @default.
• W4384559860 created "2023-07-18" @default.
• W4384559860 date "2023-07-20" @default.
• W4384559860 modified "2023-09-30" @default.
• W4384559860 title "RETROSPECTIVE COMPARATIVE STUDY ON DOCETAXEL AND CYCLOPHOSPHAMIDE VS DOXORUBICIN AND CYCLOPHOSPHAMIDE IN BREAST CANCER CHEMOTHERAPY." @default.
• W4384559860 doi "https://doi.org/10.48047/ecb/2023.12.si5.0140" @default.
• W4384559860 hasPublicationYear "2023" @default.
• W4384559860 type Work @default.
• W4384559860 citedByCount "0" @default.
• W4384559860 crossrefType "journal-article" @default.
• W4384559860 hasBestOaLocation W43845598601 @default.
• W4384559860 hasConcept C121608353 @default.
• W4384559860 hasConcept C126322002 @default.
• W4384559860 hasConcept C143998085 @default.
• W4384559860 hasConcept C2776694085 @default.
• W4384559860 hasConcept C2776755627 @default.
• W4384559860 hasConcept C2777863537 @default.
• W4384559860 hasConcept C2781190966 @default.
• W4384559860 hasConcept C2781303535 @default.
• W4384559860 hasConcept C2781413609 @default.
• W4384559860 hasConcept C530470458 @default.
• W4384559860 hasConcept C71924100 @default.
• W4384559860 hasConcept C98274493 @default.
• W4384559860 hasConceptScore W4384559860C121608353 @default.
• W4384559860 hasConceptScore W4384559860C126322002 @default.
• W4384559860 hasConceptScore W4384559860C143998085 @default.
• W4384559860 hasConceptScore W4384559860C2776694085 @default.
• W4384559860 hasConceptScore W4384559860C2776755627 @default.
• W4384559860 hasConceptScore W4384559860C2777863537 @default.
• W4384559860 hasConceptScore W4384559860C2781190966 @default.
• W4384559860 hasConceptScore W4384559860C2781303535 @default.
• W4384559860 hasConceptScore W4384559860C2781413609 @default.
• W4384559860 hasConceptScore W4384559860C530470458 @default.
• W4384559860 hasConceptScore W4384559860C71924100 @default.
• W4384559860 hasConceptScore W4384559860C98274493 @default.
• W4384559860 hasIssue "si5a" @default.
• W4384559860 hasLocation W43845598601 @default.
• W4384559860 hasOpenAccess W4384559860 @default.
• W4384559860 hasPrimaryLocation W43845598601 @default.
• W4384559860 hasRelatedWork W2000262813 @default.
• W4384559860 hasRelatedWork W2031329688 @default.
• W4384559860 hasRelatedWork W2071999249 @default.
• W4384559860 hasRelatedWork W2084370697 @default.
• W4384559860 hasRelatedWork W2091205535 @default.
• W4384559860 hasRelatedWork W2105339861 @default.
• W4384559860 hasRelatedWork W2155481114 @default.
• W4384559860 hasRelatedWork W2388730008 @default.
• W4384559860 hasRelatedWork W4229993127 @default.
• W4384559860 hasRelatedWork W4295138654 @default.
• W4384559860 hasVolume "12" @default.
• W4384559860 isParatext "false" @default.
• W4384559860 isRetracted "false" @default.
• W4384559860 workType "article" @default.